OasisLMS

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of maintenance lurbinectedin plus atezolizumab for extensive stage small cell lung cancer, based on the phase III IMforte trial. Dr. Hossein Borghaei joins the podcast to explain the results and offer perspective on the impact of maintenance therapy for SCLC.

Podcast Hosts:

• Stephen Liu, MD, Chief of Hematology and Oncology, Georgetown University, Washington, D.C., USA 

Podcast Guests: 

• Hossein Borghaei, DO, MS, Chief, Division of Thoracic Medical Oncology, Professor, Department of Hematology/Oncology, Fox Chase Cancer Center, Temple University Hospital, Philadelphia, PA, USA